The Fibromyalgia Treatment Market is trending towards an increased focus on non-drug therapies
![]() |
Fibromyalgia Treatment Market |
The
fibromyalgia treatment market is characterized by various symptoms including
chronic, widespread pain and includes treatments targeting musculoskeletal
pain, neuropathic pain, fatigue, and sleep problems associated with
fibromyalgia. Fibromyalgia therapies aim to manage symptoms through
pharmacological and non-pharmacological approaches. Commonly prescribed drugs
include duloxetine, pregabalin, and milnacipran which help relieve pain and
depression.
The
Global Fibromyalgia Treatment Market is estimated to be valued at US$ 1781.68
Bn in 2024 and is expected to exhibit a CAGR of 10% over the forecast period
from 2024 to 2030.
Key Takeaways
Key players operating in the Global
Fibromyalgia Treatment Market Demand are BASF, Syngenta, Bayer
CropScience (formerly Monsanto), DowDuPont (now Corteva), FMC Corporation,
ADAMA, Agricultural Solutions. Key players focus on developing new drug
formulations and combining pharmacological and non-drug therapies. Growing
demand for fibromyalgia treatment is being witnessed due to increasing
fibromyalgia prevalence globally and limited treatment options available. The
market is also expanding globally due increasing awareness about fibromyalgia
and associated healthcare investments in developing countries.
Market key trends
There is a growing focus on incorporating non-drug therapies like exercise,
acupuncture, mindfulness meditation and cognitive behavioral therapy along with
prescribed medications. This is due to the limitations of existing drug
therapies in providing long term relief and increasing preference for
alternative treatment approaches. Another key trend is the development of novel
drug delivery systems like transdermal patches and long acting injections to
improve medication adherence and management of fibromyalgia symptoms. Research
is also ongoing into biologics and new mechanisms of action beyond currently
approved classes of drugs to address unmet needs in fibromyalgia treatment.
Porter’s Analysis
Threat of new entrants: The biopharmaceutical industry requires high R&D investment
and clinical trial costs that deter new players.
Bargaining
power of buyers: Individual patients have little influence on prices however
public and private healthcare providers can negotiate on behalf of large
patient populations.
Bargaining
power of suppliers: The supply chain for fibromyalgia drugs is concentrated
with few major ingredient and drug formulation suppliers limiting opportunities
for forward integration.
Threat
of new substitutes: Alternative therapies provide some competition but overall
efficacy of pharmaceutical interventions remain superior though side effects
can be problematic.
Competitive
rivalry: Competition is intense as large pharmaceutical firms vie to develop
new and more effective fibromyalgia drugs to treat symptoms and potentially
modify disease progression.
Geographical regions of concentration
North America currently accounts for the largest share of the global
fibromyalgia treatment market value due to research investments and healthcare
expenditures. The United States in particular has seen rising fibromyalgia
diagnoses and treatment prescriptions fueling regional market growth.
Fastest growing region
Asia Pacific is poised to experience the fastest CAGR over the forecast period
as growing awareness, increasing healthcare access, and emerging economies'
ability to adopt new treatments drives the regional fibromyalgia treatment
market upward at a rapid pace. Expanding patient populations and rising
disposable incomes in China and India present lucrative opportunities.
For more insights, Read- https://www.rapidwebwire.com/global-fibromyalgia-treatment-market-size-and-share/
Comments
Post a Comment